Literature DB >> 12697038

Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cells.

C Palmieri1, D Roberts-Clark, A Assadi-Sabet, R C Coope, M O'Hare, A Sunters, A Hanby, M J Slade, J J Gomm, E W-F Lam, R C Coombes.   

Abstract

Keratinocyte growth factor/fibroblast growth factor 7 (KGF/FGF7) is known to be a potent growth factor for mammary cells but its origin, cellular targets and mode of action in the breast are unclear. In this study, we carried out studies to determine the localisation of FGF7 and its receptor, and the related growth factor FGF10. We also determined the factors that regulate FGF7 release from stromal cells and the effects of FGF7 on normal and neoplastic breast cells. Using an FGF7-specific antibody which does not react with the FGF7 heparan sulphate proteoglycan (HSPG)-binding site, we showed epithelial and myoepithelial immunohistochemical staining in normal breast sections, and epithelial staining in breast carcinomas. Stromal staining was also detected in some lobular carcinomas as well as a subset of invasive ductal carcinomas. FGF10 and FGF receptor (FGFR)2 immunostaining showed a similar epithelial expression pattern, whereas no stromal staining was observed. We purified normal breast stromal, epithelial and myoepithelial cells and showed that FGF7 stimulated proliferation of both epithelial cell types, but not stromal fibroblasts. We also examined the effects of FGF7 on Matrigel-embedded organoids, containing both epithelial and myoepithelial cells, and showed FGF7 induced an increase in cellular proliferation. Furthermore, conditioned medium derived from stromal cells was shown to increase the proliferation of normal and neoplastic breast epithelial cells, which could be abolished by a neutralising antibody to FGF7. Finally, we showed that interleukin-1beta, but not oestradiol or other oestrogen receptor ligands, caused a dose-related FGF7 release. Further results also indicate that the epithelial localisation of FGF7 and FGF10 in breast tissue sections is likely to be due to their binding to their cognate receptor. In summary, our findings suggest that FGF7 is a paracrine growth factor in the breast. FGF7 is produced by the breast stromal fibroblasts and has profound proliferative and morphogenic roles on both epithelial and myoepithelial cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12697038     DOI: 10.1677/joe.0.1770065

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  22 in total

Review 1.  Steroid receptors and cell cycle in normal mammary epithelium.

Authors:  Elizabeth Anderson; Robert B Clarke
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

2.  Essential role of gastric gland mucin in preventing gastric cancer in mice.

Authors:  Fumitoshi Karasawa; Akira Shiota; Yukinobu Goso; Motohiro Kobayashi; Yoshiko Sato; Junya Masumoto; Maiko Fujiwara; Shuichi Yokosawa; Takashi Muraki; Shinichi Miyagawa; Masatsugu Ueda; Michiko N Fukuda; Minoru Fukuda; Kazuhiko Ishihara; Jun Nakayama
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

3.  Inflammatory factors of the tumor microenvironment induce plasticity in nontransformed breast epithelial cells: EMT, invasion, and collapse of normally organized breast textures.

Authors:  Tal Leibovich-Rivkin; Yulia Liubomirski; Biana Bernstein; Tsipi Meshel; Adit Ben-Baruch
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 4.  Myoepithelial cells: pathology, cell separation and markers of myoepithelial differentiation.

Authors:  Catherine Clarke; Jennifer Sandle; Sunil R Lakhani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-07       Impact factor: 2.673

Review 5.  Breast cancer-associated fibroblasts: their roles in tumor initiation, progression and clinical applications.

Authors:  Aixiu Qiao; Feng Gu; Xiaojing Guo; Xinmin Zhang; Li Fu
Journal:  Front Med       Date:  2016-01-20       Impact factor: 4.592

6.  Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.

Authors:  Sunny Z Wu; Daniel L Roden; Chenfei Wang; Holly Holliday; Kate Harvey; Aurélie S Cazet; Kendelle J Murphy; Brooke Pereira; Ghamdan Al-Eryani; Nenad Bartonicek; Rui Hou; James R Torpy; Simon Junankar; Chia-Ling Chan; Chuan En Lam; Mun N Hui; Laurence Gluch; Jane Beith; Andrew Parker; Elizabeth Robbins; Davendra Segara; Cindy Mak; Caroline Cooper; Sanjay Warrier; Alistair Forrest; Joseph Powell; Sandra O'Toole; Thomas R Cox; Paul Timpson; Elgene Lim; X Shirley Liu; Alexander Swarbrick
Journal:  EMBO J       Date:  2020-08-13       Impact factor: 11.598

7.  Epimedium flavonoids counteract the side effects of glucocorticoids on hypothalamic-pituitary-adrenal axis.

Authors:  Jianhua Huang; Jijun Li; Songbai Zheng; Junzhen Wu; Wei Zhang; Tao Sun; Sheilesh Kumar Dewan; Bill Kalionis; Ziyin Shen; Xiantao Tai; Shijin Xia
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-23       Impact factor: 2.629

8.  Inflammatory mediators in breast cancer: coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition.

Authors:  Gali Soria; Maya Ofri-Shahak; Ilana Haas; Neora Yaal-Hahoshen; Leonor Leider-Trejo; Tal Leibovich-Rivkin; Polina Weitzenfeld; Tsipi Meshel; Esther Shabtai; Mordechai Gutman; Adit Ben-Baruch
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

9.  2'-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells.

Authors:  Lokesh D Nagaprashantha; Jyotsana Singhal; Shireen Chikara; Gabriel Gugiu; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  J Proteomics       Date:  2018-09-21       Impact factor: 4.044

10.  TNFα modulates Fibroblast Growth Factor Receptor 2 gene expression through the pRB/E2F1 pathway: identification of a non-canonical E2F binding motif.

Authors:  Sirio D'Amici; Simona Ceccarelli; Enrica Vescarelli; Ferdinando Romano; Luigi Frati; Cinzia Marchese; Antonio Angeloni
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.